Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to support the development of Axovia’s gene therapies, including AXV101, for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.
Lead Product(s): AXV101
Therapeutic Area: Genetic Disease Product Name: AXV101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Charles River Laboratories, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 09, 2024
Details:
Axovia is developing the first gene therapies for ciliopathies and has a pipeline of products, including AXV101, an AAV9-based gene therapy targeting retinal dystrophy associated with BBS in patients carrying biallelic mutations in the BBS1 gene.
Lead Product(s): AXV101
Therapeutic Area: Genetic Disease Product Name: AXV101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ALSA Ventures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 19, 2023